Navigation Links
Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters
Date:1/28/2009

PHILADELPHIA and LONDON, Jan. 28 /PRNewswire/ -- The Scientific business of Thomson Reuters today announced the results of a study showing that the United States' share of scientific research output continues to shrink while Asia-Pacific's share of output rises. Nevertheless, the U.S. retains a healthy footing globally in the relative impact of its research.

In its January/February issue of Science Watch, Thomson Reuters analyzes 12 year's worth of data from its National Science Indicators database to determine the U.S.'s global scientific influence based on the nation's research output and impact.

In 2005, Science Watch noted that the U.S.'s output, as a percentage of world science, was in decline, with Asia-Pacific's output steadily rising. This latest analysis shows the trends continuing. In 2005, the U.S. contributed 32.8 percent of global research; by 2007 its share slid to 31.5 percent. During the same period, Asia-Pacific's share increased from 25.9 percent to 28.2 percent.

"It is important to note that measuring scientific output is only one way to measure a country's influence in the sciences," said Christopher King, editor of Science Watch. "Because citations are an acknowledgement of intellectual debt, we also evaluate a country's citation impact. The U.S.'s citation impact has remained strong in the major science fields."

In all 21 science fields analyzed for this report, the U.S. markedly surpassed the world average in citation impact. Topping the list was Physics, where the U.S. exceeded the world mark by 55 percent, followed by Chemistry and Materials Science where the U.S. exceeded the world by 52 percent and 47 percent, respectively.

For more information about U.S. research output and impact, including expert analysis, visit ScienceWatch.com.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Fadel Partners Announces 13% Growth Despite IT Services Industry Downtrend
2. Despite Economic Woes, Physician Compensation Increases
3. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
4. Multigene Test Predicts Who Could Avoid Chemotherapy Despite Positive Lymph Nodes in Early Breast Cancer
5. Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008
6. Data show a decline in cystic fibrosis since introduction of prenatal carrier screening
7. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
8. Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders
9. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
10. IntraLinks Poll: Half of Clinical Trial Management Professionals Share Critical Information Via E-Mail
11. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage ... find a better treatment for triple negative breast cancer (TNBC), ... France program. The YEi Start ... designed to help entrepreneurs grow their business in ... eight American companies selected to complete an intensive one week ...
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
(Date:2/16/2017)... Feb. 16, 2017   Biostage, Inc. (Nasdaq: ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, announced today the closing on February 15, 2017 ... of common stock and warrants to purchase 20,000,000 shares ... million. The offering was priced at $0.40 per share ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, today ... 1a financing and entered into a $5 million ... intends to use the capital for general corporate ... advancements in the treatment of serious diseases treated ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):